Takeda's Zasocitinib Shows About 70% Of Patients Achieving Clear Or Almost Clear Skin At Week 16 In Phase 3 LATITUDE PsO Studies Of Nearly 3,000 Patients
Acceptance is based on pivotal Phase 3 data demonstrating rapid, durable and consistent skin clearance, including in high-impact sites, in a convenient once-daily pillResults from nearly 3,000 patients support potential
Share
Why It Matters
Takeda's new skin medicine helped most patients get clear skin. This is good news about the medicine working in big trials.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.